Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, randomized, parallel group, multicenter, multinational study for the evaluation of safety of four fixed dose regimens of DU 176b in subjects with non-valvular atrial fibrillation

Next Previous
X
Search
Trial Profile

A phase 2, randomized, parallel group, multicenter, multinational study for the evaluation of safety of four fixed dose regimens of DU 176b in subjects with non-valvular atrial fibrillation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Biomarker
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 1146 to 2000 as reported by European Clinical Trials Database.
    • 18 Aug 2009 Results reported at 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 08 Dec 2008 Results were presented at the 50th Annual Meeting of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top